February 17th 2025
Catch up on coverage from the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update.
January 23rd 2025
Here's how best to manage polypharmacy in patients with traumatic brain injury.
More Than ‘Blue’ After Birth: Managing Diagnosis and Treatment of Post-Partum Depression
View More
Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans
View More
Expert Perspectives in the Recognition and Management of Postpartum Depression
View More
Southern California Psychiatry Conference
July 11-12, 2025
Register Now!
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists
View More
BURST CME™ Part I: Understanding the Impact of Huntington’s Disease
View More
Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease
View More
Treatment approach for a mother experiencing PPD already on SSRI
February 14th 2025Melanie Barrett, MD; Anita Clayton, MD, and Carmen Kosicek, MSN, PMHNP-BC, discuss how optimizing SSRI dosage, potentially augmenting with another medication class, and intensifying psychosocial support helps address breakthrough PPD symptoms in mothers with partial response to current SSRI treatment.
A case of a mother experiencing PPD while on low-dose SSRI
February 14th 2025Melanie Barrett, MD; Anita Clayton, MD, and Carmen Kosicek, MSN, PMHNP-BC, discuss how a mother's persistent PPD symptoms despite SSRI treatment necessitated a comprehensive reevaluation of medication dosage, additional therapeutic interventions, and closer monitoring of treatment response to achieve better symptom control.
AXS-05 Demonstrates Efficacy and Manageable Adverse Effects in Major Depressive Disorder Treatment
February 12th 2025A pooled analysis of two clinical trials highlights AXS-05’s rapid and sustained effectiveness in reducing depressive symptoms, offering a promising new treatment option for major depressive disorder with a manageable safety profile.
SPN-820 Shows Rapid and Significant Improvement in Major Depressive Disorder Symptoms
February 12th 2025A new phase 2 trial reveals a novel antidepressant delivers rapid symptom relief for major depressive disorder, with patients experiencing significant improvement within just hours of their first dose.